share_log

Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target

Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target

Needham重申对Viridian Therapeutics的买入评级,维持38美元的目标股价
Benzinga ·  01/07 03:34  · 评级/大行评级

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $38 price target.

Needham分析师Serge Belanger重申了Viridian Therapeutics(纳斯达克:VRDN)的买入评级,并维持38美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发